NEW YORK (GenomeWeb News) – Agilent Technologies today announced a collaboration with Florida International University to develop methods for the identification and characterization of designer drugs.

Agilent is working with FIU's department of chemistry and biochemistry and its International Forensics Research Institute and is currently focused on developing and validating methods for rapid forensic screening and analysis to expand the capabilities of drug screening techniques using immunoassays, the company said.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

In an against-all-odds twist, a researcher studying exceeding rare FOXG1 mutations discovers her daughter has the syndrome.

An effort by Genomics Medicine Ireland is creating a database of diseases based on the genomics of people in Ireland. It now is looking into the possibility of including Scotland in its work.

In recent weeks, the direct-to-consumer genetics firm has rolled out a health hub where customers can share information concerning 18 common health conditions.

In PLOS this week, new genes associated with prostate cancer risk, genetic patterns in M. bovis, and more.